Evidence map›Paper›PMID 42368564›Full record

ArticleActa pharmaceutica Sinica. B2026

(+)-Miliusol suppresses the Warburg effect and induces regulated cell death in triple-negative breast cancer through targeting EIF3D and remodeling cancer metabolism.

Jin Zhang, Lin Jia, Xiya Chen, Yan Wu, Xiaohan Sun, Ling Zou, Xiaoling Cheng, Jingnan Huang, Hongchao Zhou, Lingyun Dai and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jin ZhangSchool of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China.
Lin JiaCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Xiya ChenSchool of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China.
Yan WuSchool of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China.
Xiaohan SunCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Ling ZouDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Xiaoling ChengSchool of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China.
Jingnan HuangDepartment of Geriatrics, and Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518020, China.
Hongchao ZhouDepartment of Geriatrics, and Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518020, China.
Lingyun DaiDepartment of Geriatrics, and Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518020, China.
Le ZhouCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Zhendan HeCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Bo LiuDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Yue HaoSchool of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China.
Dahong YaoCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) exhibits marked molecular heterogeneity, posing ongoing therapeutic challenges. Metabolic reprogramming, particularly through the Warburg effect, offers a promising therapeutic target for TNBC treatment. Data mining and machine learning identified (+)-miliusol as a promising candidate. Its direct target, eukaryotic initiation factor 3D (EIF3D), was validated through mass spectrometry-coupled cellular thermal shift assay (MS-CETSA), a biotinylated probe, and a proteolysis-targeting chimera (PROTAC) approach. EIF3D, an emerging oncoprotein and atypical translation initiation regulator, promotes tumor survival by selectively modulating protein synthesis. (+)-Miliusol demonstrates potent anti-proliferative and anti-migratory activity against TNBC in both

Indexed as

AutophagyEIF3DER stressMetabolic reprogramming(+)-MiliusolTNBCWarburg effect

Identifiers

PMID42368564
PMCPMC13304780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.